NRP1 and acute lymphoblastic leukemia: Furthermore, using FMC, Abaza et al. suggested that NRP-1/CD304 expression could serve as a reliable tool for distinguishing leukemic B-lymphoblasts from normal counterparts, offering a stable phenotype for minimal residual disease monitoring and potentially indicating poor prognosis in pediatric precursor B-ALL [114].